EP0578774B1 - Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor - Google Patents

Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor Download PDF

Info

Publication number
EP0578774B1
EP0578774B1 EP92910836A EP92910836A EP0578774B1 EP 0578774 B1 EP0578774 B1 EP 0578774B1 EP 92910836 A EP92910836 A EP 92910836A EP 92910836 A EP92910836 A EP 92910836A EP 0578774 B1 EP0578774 B1 EP 0578774B1
Authority
EP
European Patent Office
Prior art keywords
cells
monoclonal antibody
scf
antibody according
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP92910836A
Other languages
English (en)
French (fr)
Other versions
EP0578774A4 (en
EP0578774A1 (de
Inventor
Nancy Lin
Virginia C. Broudy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of EP0578774A1 publication Critical patent/EP0578774A1/de
Publication of EP0578774A4 publication Critical patent/EP0578774A4/en
Application granted granted Critical
Publication of EP0578774B1 publication Critical patent/EP0578774B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Definitions

  • the present invention relates to monoclonal antibodies specific for a cell receptor that binds human stem cell factor (hSCF), as well as pharmaceutical compositions containing such monoclonal antibodies and uses of such monoclonal antibodies.
  • hSCF human stem cell factor
  • SCF Stem Cell Factor
  • the proto-oncogene c-kit has recently been identified as the receptor for SCF [Zsebo et al., Cell 63 :213-224 (1990)].
  • the c-kit receptor Prior to identification of c-kit as the ligand for SCF, the c-kit receptor was known to exist [Yarden et al., EMBO J. 6:3341-3351 (1987); Qiu et al., EMBO J. 7:1003-1011 (1988); Flanagan and Leder, Cell 63 :185-194 (1990)].
  • the present invention relates to a monoclonal antibody comprising a monoclonal antibody having an ability to bind to an SCF receptor.
  • the binding of the monoclonal antibody to the SCF receptor will also inhibit binding of an SCF molecule to said SCF receptor.
  • the SCF and the SCF receptor will be of human origin.
  • the SCF receptor monoclonal antibodies are used in a method of purifying hematopoietic cells comprising the steps of:
  • the hematopoietic cells purified with the SCF receptor monoclonal antibodies are used in a method of reconstituting hematopoietic cells comprising bone marrow transplantation.
  • the hematopoietic cells purified with the SCF receptor monoclonal antibodies are used in a method of gene therapy comprising retrovirally-mediated gene transfer into the purified cells.
  • Another aspect of the present invention relates to a method of separating normal cells from neoplastic cells comprising the steps of:
  • Another aspect of the present invention relates to use of the SCF receptor monoclonal antibodies for treating neoplastic cells by administration of a therapeutically effective amount of an anti-neoplastic therapeutic agent conjugated to such a monoclonal antibody.
  • the present invention also relates to a method of treating neoplastic cells comprising administration of a therapeutically effective amount of a neoplastic therapeutic agent conjugated to a binding fragment of a monoclonal antibody of the present invention.
  • Another aspect of the present invention relates to a method of determining the presence of SCF receptors in a cell sample comprising the steps of:
  • the monoclonal antibodies of the present invention are also useful as a method of modifying sensitivity to cell cycle-specific chemotherapeutic agents comprising administration of a SCF-inhibiting amount of a monoclonal antibody of the present invention.
  • Figure 1 Scatchard analysis of 125 IhSCF binding to human fetal liver cells. 0.9 X 10 6 fetal liver cells were incubated with 125 IhSCF (5 picomolar to 2 nanomolar) and 100 fold excess unlabelled hSCF for 4 hours at 15°C.
  • FIG. 2 Effect of recombinant human SCF (rHuSCF)on the growth of acute nonlymphocytic leukemia cells when administered alone or in combination with other growth factors such as interleukin-3.
  • rHuSCF recombinant human SCF
  • Figure 3 Scatchard plot of 125 IhSCF binding to blasts from a patient with acute nonlymphocytic leukemia (ANLL).
  • ANLL acute nonlymphocytic leukemia
  • Figure 4 Scatchard analysis of 125 IhSCF binding to human small cell lung cancer cells. 0.2 x 10 6 small cell lung cancer cells (H69 cell line) were incubated with 125 IhSCF (5 picomolar to 2 nanomolar) and 100 fold excess unlabelled hSCF for 4 hours at 15°C.
  • Figure 5 Scatchard plot of 125 IhSCF binding to OCIM1 cells.
  • Figure 6 Indirect immunofluorescence analysis of SCF binding to normal human bone marrow.
  • the bone marrow cells were simultaneously labelled with anti-CD34 monoclonal antibody and with either SR-1 ( Figure 7A) or with an isotype matched control monoclonal antibody (anti-Thy 1.1), ( Figure 7B).
  • FIG. 7 Recognition of the SCF receptor, c-kit , by monoclonal antibody SR-1.
  • COS-1 cells were transfected with V19.8 or V19.8 containing human c-kit .
  • the COS cell membranes were incubated with 1 nanomolar 125 IhSCF with or without cold SCF or SR-1 ascities (diluted 1:1000) and bound labelled SCF was measured.
  • the present invention relates to a monoclonal antibody comprising a monoclonal antibody having an ability to bind to an SCF receptor.
  • the binding of the monoclonal antibody to the SCF receptor will also inhibit binding of an SCF molecule to said SCF receptor.
  • the SCF and the SCF receptor will be of human origin. More preferably, the monoclonal antibody will be of the IgG2a isotype.
  • Such a monoclonal antibody can be obtained by general methods, including the steps of immunizing or sensitizing an animal with an antigen or immunogen, obtaining the antibody-producing cells resulting therefrom, fusing such antibody producing cells to a stable and long living cell line (an immortal cell line) to produce hybridomas, screening the hybridomas to select a colony consisting of cells that produce the desired antibody, and isolating the resulting monoclonal antibody from such cells.
  • Sensitization can be accomplished by injecting the antigen into an antibody producing species.
  • the injection will be into a mammal and more preferably into mice.
  • an initial injection is given followed by subsequent booster injections to maximize the response.
  • the injection regime is in multiple doses given to Balb/C mice, e.g., one injection intraperitoneally per week for three consecutive weeks.
  • the amount of antigen injected must be adequate to elicit a sufficient amount of antibody to be detectable.
  • Preferred amounts of antigen to be injected are 10 4 to 10 8 cells containing SCF receptors, preferably 10 5 to 10 7 cells containing SCF receptors, most preferably about 10 6 cells containing SCF receptors.
  • variable region of the mouse monoclonal antibody can also be genetically engineered onto the constant region of a human immunoglobulin which may be preferable for use in humans to prevent problems of immunogenicity often associated with administration of foreign proteins to humans.
  • chimeric antibodies can be obtained by splicing genes encoding the variable antigen-binding regions of a human antibody molecule to the constant regions of a human antibody molecule [Sahagan et al., J. Immunol. 137 :106601074 (1986); Beidler et al., J . Immunol. 141 :4053-4060 (1988); Morrison et al., Ann. N.Y. Acad. Sci. 507:187-198 (1988)].
  • a further refinement envisioned within the present invention is production of chimeric antibodies containing a murine hypervariable region coupled to human constant and framework variable regions [Reichman et al., Nature 332:323-327 (1988)].
  • Most antigen specificity resides in defined segments of the V regions (hypervariable regions) or CDR regions (complementary-determining regions).
  • Antigen-combining sites are formed by CDR loops extending from the remaining framework portions of the V regions.
  • Host immune responses may be generated against the less variable rodent framework V regions of chimeric antibodies.
  • Chimeric antibodies containing human framework V regions retain the antigen binding specificity conferred by the murine CDR regions but are unlikely to elicit a host immune response.
  • Total gene synthesis is the most practical method of preparing CDR-replaced variants in which CDRs from a rodent antibody are transplanted into a human framework. Following sequencing of the desired V region, the sequence is chemically synthesized, cloned, and then inserted into an appropriate expression vector.
  • the antigens that are useful in producing the monoclonal antibodies of the present invention are any cell line that displays an SCF receptor on its surface.
  • Such cell lines include the human erythroleukemia cell lines OCIM1 [Papayannopoulou et al., Blood 72:1029-1038(1988)], K562 (ATCC CCL 243); the myeloid or monocytic cell lines KG1 (ATCC CCL 246), KG1 ⁇ (ATCC CCL 246.1), AML-193 [Santoli et al., J.
  • Preferred antigens are the human erythroleukemia cell line OCIM1.
  • the sensitized animal will produce B-cells that produce and secrete antibodies specific for the antigen.
  • Such cells can be isolated for further use by removing the spleen of the immunized mouse
  • Suitable cell lines for fusion to the antibody producing cells are any cell line that lacks the ability to synthesize antibodies, preferably also lacking in the ability to grow on medium containing a selection agent, most preferably possessing the mutant hypoxanthine-guanidine phosphoribosyl transferase gene (HGPRT- gene), which cannot produce the active hypoxanthine-guanidine phosphoribosyl transferase protein.
  • HGPRT- gene mutant hypoxanthine-guanidine phosphoribosyl transferase gene
  • hypoxanthine-guanidine phosphoribosyl transferase is necessary to grow on a medium containing aminopterin.
  • Such cell lines that are preferred include myeloma cells, more preferably the NS-1 murine myeloma cell line [ATCC T1B 18; Nowinski et al., Virology 93:111-126 (1979)].
  • NS-1 murine myeloma cell line ATCC T1B 18; Nowinski et al., Virology 93:111-126 (1979)].
  • Recently, there has even been success in using human cell lines as fusion partners [Banchereau et al., Science 251 :70-72 (1991)].
  • the resulting fusion partners can then be screened to select a colony consisting of cells that produce the desired antibody. Screening techniques are known in the art, and usually involve the growing of the fused cells on a medium containing a selection agent that (1) would lead to the death of the unfused immortal cells when such immortal cells lack the ability to circumvent the selection agent but (2) allow growth of cells containing genetic material from the antibody producing cell when such genetic material contains the potential to circumvent the selection agent.
  • a preferred immortal cell line contains the HGPRT- gene and a preferred medium contains aminopterin, more preferably the medium hypoxanthine aminopterin thymidine (HAT). As a result, only the fusion cells having both the HGPRT+ gene from the antibody producing cell line and the characteristic of immortality from the immortal cell line would survive and grow in the medium.
  • the successful fusion cells, or hybridomas can then be screened to determine if they have the ability to produce antibodies to the antigen used for sensitization.
  • screening can be by the ability of the hybridoma products to bind to SCF receptors, the ability of the hybridoma products to inhibit binding of SCF to SCF receptors, or by standard immunological techniques (e.g., immunoprecipitation of radiolabelled purified SCF receptor) or by ability of the hybridoma products to recognize purified SCF receptor in an ELISA assay.
  • the hybridomas can be screened by the ability of hybridoma products to block binding of SCF to SCF receptors.
  • SCFs Stem cell factors useful in these assays include any of the SCFs from various species. Such SCFs are usually in solution with a suitable adjuvant, which adjuvant may contain buffers, salts, etc.
  • the SCF will be a human SCF (HuSCF), more preferably a recombinant human SCF (rHuSCF), and most preferably a rHuSCF produced in E. coli.
  • Human SCF human SCF
  • rHuSCF recombinant human SCF
  • rHuSCF recombinant human SCF
  • rHuSCF recombinant human SCF
  • hybridomas that are positive for secretion of antibodies to the SCF receptor can then be subcloned and essentially maintained indefinitely.
  • Such selected hybridomas can also be cultured for the production of the monoclonal antibodies that they secrete.
  • the desired monoclonal antibody can be isolated from a culture of such hybridomas using techniques that are known in the art, including protein A-sepharose column chromatography [Ey et al.,
  • the preferred monoclonal antibodies of the present invention are those designated SR-1, deposited as BA7.3C.9 with the American Type Culture Collection, Rockville, Maryland, USA on April 4, 1991, and given the Accession Number HB10716.
  • the monoclonal antibodies of the present invention can be used in a method of purifying hematopoietic cells comprising the steps of:
  • a cell mixture to such monoclonal antibodies can be in solution, as is the case with fluorescence-activated cell sorting, or it can be with the monoclonal antibody immobilized on a solid support, such as is the case with column chromatography or direct immune adherence.
  • a combination of soluble and solid support monoclonal antibodies can be used to expose the cell mixture to such monoclonal antibodies, as has been the case with anti-CD34 antibody and a biotinylated second antibody put through an avidin column to remove breast cancer cells in human transplants [Bensinger et al., J. Clin. Apheresis 5:74-76 (1990); Berenson et al., Blood 76:509-515 (1986)].
  • the mixture of cells that is to be exposed to the monoclonal antibody can be any solution of bone marrow cells, blood cells or tissue cells.
  • the cell mixture is from mammalian bone marrow, circulating blood, or suspected tumor tissue.
  • those cells with SCF receptors will bind to the monoclonal antibody to form an antibody-SCF-receptor-cell complex.
  • SCF receptor cell complexes can then be separated from noncomplexed cells by methods that are known in the art. Preferred methods of separation include column chromatography, fluorescence-activated cell sorting, magnetic bead separation, and direct immune adherence.
  • the hematopoietic cells thus purified can be employed in a method of reconstituting hematopoietic cells comprising bone marrow transplantation.
  • Methods of bone marrow transplantation are known in the art [Hill et al., Bone Marrow Transplant. 4:69-74 (1989)], but heretofore it has not been possible to use such a homogeneous population of cells having SCF receptors as the material transplanted.
  • Such cells are responsible for long term engraftment in a bone marrow transplant and can be separated from contaminating tumor cells that may be present in the bone marrow using the methods described above.
  • the cells having SCF receptors purified by the purification method of the present invention can be further subfractionated to obtain even more homogeneous cell populations.
  • a population of SCF-receptor-containing cells can be sequentially exposed to monoclonal antibodies specific for other cell surface proteins that occur on only certain subpopulations of the SCF-receptor-containing cells.
  • monoclonal antibodies that can be used in such a sequential method of purification include monoclonal antibodies to the CD34 antigen which is also expressed on hematopoietic stem cells [Andrews et al., J. Exp. Med. 169:1721-1731 (1989); Civin, United States Patent 4,965,204, issued October 23, 1990; Civin, European Patent Application 395355, published October 31, 1990].
  • Hematopoietic cells purified according to the present invention can also be used in a method of gene therapy comprising retrovirally-mediated gene transfer into the purified cells.
  • Methods of retrovirally-mediated gene transfer are known in the art [Bodine et al., Proc. Natl. Acad. Sci. USA 86:8897-8901 (1989)], but heretofore it has not been possible to use such a homogeneous population of cells having SCF receptors as the cells transfected. Such transfected cells can then be used in bone marrow transplantation.
  • the present invention also relates to a method of separating normal cells from neoplastic cells comprising the steps of:
  • the monoclonal antibodies of the present invention can also be useful in treating neoplastic cells by administration of a therapeutically effective amount of an anti-neoplastic therapeutic agent conjugated to such a monoclonal antibody.
  • a therapeutically effective amount of a neoplastic therapeutic agent is any amount of a compound that will cause inhibition of growth and/or development of neoplastic cells, preferably causing death of the cell and a decrease in the total number of neoplastic cells in an organism.
  • neoplastic therapeutic agents include antibodies coupled to the radioisotope 125 I [Press et al., J. Clin. Oncol.
  • the conjugation site on the monoclonal antibody is at a location distinct from the binding site for the monoclonal antibody to the SCF receptor. It is also preferred that the conjugation site on the neoplastic therapeutic agent be at a functional group distinct from the active site of the therapeutic agent. More preferably, the conjugation site will also be situated so as to minimize conformational changes of the monoclonal antibody or the neoplastic therapeutic agent.
  • the present invention also relates to a method of treating neoplastic cells comprising administration of a therapeutically effective amount of a neoplastic therapeutic agent conjugated to a binding fragment of a monoclonal antibody of the present invention.
  • Suitable binding fragments are those fragments that retain sufficient size and structure to allow binding of the fragment to the SCF receptor.
  • Such fragments can be prepared by numerous methods, including proteolytic digestion [Garvey et al., Methods in Immunology, Chapter 31, W.A. Benjamin, Reading, Massachusetts (1977)]. The prepared binding fragments can be assayed for ability to bind to the SCF receptor using the binding assays previously described.
  • Another use of the monoclonal antibodies of the present invention relates to a method of determining the presence of SCF receptors in a cell sample comprising the steps of:
  • the exposure of a cell mixture to such monoclonal antibodies can be in solution, as is the case for fluorescence-activated cell sorting, or it can be on solid tissue specimens such as biopsy material, or it can be with the monoclonal antibody immobilized on a solid support, as is the case with column chromatography or direct immune adherence.
  • the mixture of cells that is to be exposed to the monoclonal antibody can be any solution of blood cells or tissue cells.
  • the cell mixture is from normal mammalian cells, mammalian bone marrow, circulating blood, or suspected tumor tissue, more preferably normal cells, leukemia cells and solid tumor cells.
  • the monoclonal antibodies of the present invention are also useful as a method of modifying sensitivity to cell cycle-specific chemotherapeutic agents comprising administration of a SCF-inhibiting amount of a monoclonal antibody of the present invention.
  • An SCF-inhibiting amount of a monoclonal antibody is sufficient quantities of monoclonal antibody to significantly inhibit the binding of SCF to its receptor or to significantly decrease the growth and development of cells containing the SCF receptor, e.g., early pluripotent hematopoietic progenitors, leukemia cells, solid tumor cells, bone marrow cells.
  • a significant inhibition is inhibition that is larger than the variance due to error expected with a given method of measuring the inhibition.
  • the inhibition will decrease binding of SCF to its receptor by at least 50%, more preferably by at least 75%, more preferably by at least 90%, and most preferably inhibition will decrease binding of SCF to its receptor essentially entirely.
  • a significant decrease of the growth and/or development of cells containing the SCF receptor is a decrease larger than the variance due to error expected with a given method of measuring the growth and/or development.
  • decrease of the growth and/or development of cells containing the SCF receptor is a lowering of the growth rate of SCF-receptor-containing cells, preferably a decrease to at least one-half, more preferably to at least one-tenth, and most preferably to at least one-hundredth.
  • Administration of the monoclonal antibodies of the present invention involves administration of an appropriate amount of a pharmaceutical composition containing the monoclonal antibodies as an active ingredient.
  • the pharmaceutical composition may also include appropriate buffers, diluents and additives.
  • Appropriate buffers include Tris-HCl, acetate, glycine and phosphate, preferably phosphate at pH 6.5 to 7.5.
  • Appropriate diluents include sterile aqueous solutions adjusted to isotonicity with NaCl, lactose or mannitol, preferably NaCl.
  • Appropriate additives include albumin or helatin to prevent adsorption to surfaces, detergents (e.g., Tween® 20, Tween® 80, Pluronic® F68), solubilizing agents (e.g., glycerol, plyethylene glycol), antioxidants (e.g., ascorbic acid, sodium metabisulfite) and preservatives (e.g., Thimersol, benzyl alcohol, parabens).
  • detergents e.g., Tween® 20, Tween® 80, Pluronic® F68
  • solubilizing agents e.g., glycerol, plyethylene glycol
  • antioxidants e.g., ascorbic acid, sodium metabisulfite
  • preservatives e.g., Thimersol, benzyl alcohol, parabens.
  • a preferred additive is Tween® 80.
  • Administration may be by any conventional means including intravenously, subcutaneously, or intramuscularly.
  • the preferred route of administration is intravenous.
  • Administration may be a single dose or may occur in an appropriate number of divided doses.
  • the pharmaceutical preparation is in unit dosage form.
  • the preparation is subdivided into unit doses containing the appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • the actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered essentially continuously or in portions during the day if desired. The amount and frequency of administration will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the disease being treated.
  • a typical recommended dosage regime for use in the present invention is from about 0.1 to about 10 mg active ingredient per kg body weight per day.
  • Appropriate antigens for use in sensitization were any cell displaying SCF receptors.
  • the presence of SCF receptors was determined using radiolabelled SCF.
  • Human and rodent SCF 164-165 was obtained according to the methods of Zsebo et al., Cell 63:195-212 (1990); and EP-A-0-423 980. These SCFs were labelled with 125 I using the chloramine-T method of Hunter and Greenwood [Nature 194 :495-496 (1962)].
  • the specific activity of the 125 I human SCF (hSCF) varied from 2,000 to 2,500 Ci/mmol.
  • Both 125 I hSCF and 125 I rat SCF (rSCF) retained the ability to bind to SCF-receptor-containing cells.
  • SCF receptors Numerous normal hematopoietic cells, hematopoietic cell lines and neoplastic nonhematopoietic cells were screened for expression of SCF receptors.
  • Normal human marrow mononuclear cells bind hSCF, as do human fetal liver early erythroblasts.
  • Adult late erythroblasts which were obtained by culturing peripheral blood BFU-E and plucking individual colonies after 14 days, also displayed SCF receptors. Distribution of SCF receptors on normal human marrow cells were determined by autoradiography [Nicola and Metcalf, J. Cell Physiol. 124:313-321 (1985)]. Large cells with high nuclear/cytoplasmic ratio that appeared to be blasts and promyelocytes were densely labelled with approximately 50 to 200 grains per cell.
  • a number of human hematopoietic cell lines displayed SCF receptors.
  • the erythroleukemia cell lines OCIM1 and K562 bind SCF, as do the myeloid of monocytic cell lines KG-1, KG1a, AML-193 and U937.
  • the lymphoid cell lines Daudi and IM-9 and the mast cell line HMC-1 all bound SCF.
  • SCF receptors were also found on nonhematopoietic cell lines including the bladder carcinoma line 5367, COS, BHK, the gastric carcinoma cell line KATO3, the small cell carcinoma cell lines H69 and H128, and the breast carcinoma cell line DU475.
  • SCF receptors were quantitated on normal human fetal liver cells and examined for their response to SCF in colony assays.
  • Human fetal liver cells (gestational age 55 to 80 days) were obtained from therapeutic abortions. Consent was obtained for the use of these tissues, and the studies were approved by the Institutional Review Board at the University of Washington. The cells were incubated with 125 IhSCF (5 picomolar to 2 nanomolar) ⁇ a 100 fold excess of unlabelled SCF for 4 hours at 15°C in the presence of metabolic inhibitors. Under these conditions, the equilibrium binding for SCF is achieved and internalization is minimal ( ⁇ 17%).
  • cell-associated 125 IhSCF was separated from free 125 IhSCF by sedimenting the cells through phthalate oil, as described in Broudy et al., Blood 75 :1622-1626 (1990). Equations for 1 or 2 classes of receptors were fitted to the data using a ligand program [Munson and Rodbard, Analyt. Biochem. 107:220-239 (1980)].
  • the human fetal liver cells were found to express 2 classes of SCF receptors as shown in Figure 1.
  • the high affinity receptor had a Kd of 14 picomolar and the low affinity receptor had a Kd of 2.7 nanomolar with approximately 1,700 receptors/cell.
  • Neoplastic hematopoietic cells were investigated to determine whether they would also respond to SCF and display SCF receptors.
  • Marrow mononuclear cells from 20 different patients with acute nonlymphocytic leukemia (ANLL) at first presentation and two normal adults were studied.
  • the cells were cultured in agar supplemented with 15% fetal calf serum and recombinant human IL-3. Colonies (>40 cells) and clusters ( ⁇ 40 cells) were counted after 8, 15, and 21 days.
  • SCF receptors were quantified by equilibrium binding studies with 125IhSCF ⁇ a 100 fold excess of unlabelled hSCF. The cellular distribution of SCF receptors was examined by autoradiography.
  • SCF stimulated colony growth from 7 of the 20 ANLL marrows studied and from both of the normal marrows. SCF alone had little effect on colony growth, but acted synergistically with IL-3 to increase both the number and size of colonies (Figure 2).
  • Receptors for SCF were identified on the blasts of all 20 ANLL patients. Ten of the 20 ANLL patients exhibited 2 classes of SCF receptors on their marrow blasts.
  • a Scatchard plot of 125 IhSCF binding to the blasts from one of the ANLL patients shows approximately 500 high affinity SCF receptors (Kd 16 picomolar) and 7000 low affinity receptors (Kd 7.6 nanomolar) per cell as illustrated in Figure 3.
  • binding affinities are similar to those found on normal human fetal liver cells and normal human marrow mononuclear cells.
  • Six of the 20 patients showed a single class of high affinity receptors, while the remaining patients showed a single low affinity binding site. Neither the number of receptors/cell nor the presence of 1 or 2 classes of receptors correlated with growth response to SCF, as has been observed for IL-3, GM-CSF and G-CSF receptors on human ANLL blasts [Park et al., Blood 74:56-65 (1989)].
  • the marrow mononuclear cells from these leukemic patients were greater than 90% blasts while marrow mononuclear cells from normal adults contain a much lower fraction of blasts.
  • the vast difference in the percentage of blasts suggests that it is not accurate to compare the average number of receptors per cell on normal and leukemic marrow samples.
  • Autoradiography which permits analysis of binding to individual cells, can more accurately be used to compare SCF binding to normal and leukemic blasts.
  • Autoradiographic analysis of 125 IhSCF binding to normal human marrow mononuclear cells on 8 of the ANLL marrow samples was carried out in a single experiment to permit direct comparison.
  • SCF receptors were also found on tumor cell lines of non-hematopoietic origin including H69, H128, and DU475.
  • a Scatchard plot of 125 IhSCF binding to H69 cells shows 1650 high affinity receptors per cell (Kd 37 picomolar) and 22,300 receptors per cell (Kd 7.2 nanomolar).
  • OCIM1 is a human erythroleukemia cell line that displays receptors for erythropoietin [Broudy et al., Proc. Natl. Acad. Sci. USA 85:6513-6517 (1988)], GM-CSF, and IL-3. Equilibrium binding studies with 125 IhSCF showed that OCIM1 cells display about 200,000 SCF receptors per cell as shown in Figure 5. A single class of high affinity SCF receptors (Kd 45 picomolar) is evident. hSCF did not stimulate the growth of OCIM1 cells in suspension culture.
  • MB-02 is a growth factor dependent human erythroleukemia cell line that will undergo erythroid differentiation in the presence of erythropoietin [Perrine et al., Biochem. Biophys. Res. Comm. 164 :857-862 (1989)].
  • MB-02 cells respond to hSCF with proliferation, but not erythroid differentiation, and display both high and low affinity SCF receptors.
  • the OCIM1 cells were used as an immunogen because of their high SCF receptor display, although any cell displaying SCF receptors could be used as an immunogen to elicit antibodies to the SCF receptor.
  • spleen Five days following the third injection, the spleen was removed and splenic cells were fused with NS-1 murine myeloma cells [Nowinski et al., Virology 93:111-126 (1979)].
  • the supernatants from a total of 288 hybridoma wells were screened for the ability to block binding of 125 IhSCF to OCIM1 cells as described in Example 5, below.
  • a positive hybridoma was identified, cloned and grown as an ascites-producing tumor in pristane-primed Balb/C mice.
  • the antibody was identified as IgG2a and was named SR-1 (deposited as BA7.3C.9 with the American Type Culture Collection, Rockville, Maryland USA on April 4, 1991 and given the ATCC Accession Number HB10716). Screening of additional hybridomas should lead to the identification of additional anti-SCF receptor monoclonal antibodies at a similar frequency.
  • Example 3 Production of Chimeric Monoclonal Antibodies Having Murine Variable Regions and Human Constant Regions.
  • Genomic DNA is prepared from the hybridoma cell line producing SR-1 monoclonal antibodies, and functional exons encoding the variable regions of heavy and light chains (V H and V ⁇ , respectively) are identified by DNA restriction maps obtained by Southern analysis. Functional V ⁇ exons result when germline V ⁇ genes are rearranged and joined to the JK gene segment. Similarly, a functional V H exon is created when a V H gene is juxtaposed to the JH gene segment. Specific DNA probe segments are designed to identify rearranged V-regions genes via unique restriction enzyme sites that distinguish the rearranged genotype from the unrearranged germline DNA sequences [Oi and Morrison, BioTechniques 4:214-221 (1986)].
  • V H exon is inserted into the pSV2 ⁇ Hgpt vector [Mulligan and Berg, Science 209 :1422-1427 (1980); Mulligan and Berg, Proc. Natl. Acad. Sci. USA 78 :2072-2076 (1981)], which contains an ampicillin resistance gene to maintain the plasmid in E. coli, and a mycophenolic acid resistance gene to permit selection in mammalian cells growing in medium containing hypoxanthine, mycophenolic acid and xanthine.
  • the desired V ⁇ exon is inserted into the pSV184 ⁇ Hneo vector, which is derived from the pACYC184 plasmid [Chang and Cohen, J. Bacteriol. 143:1141-1156 (1978)].
  • This vector contains a chloramphenicol resistance gene used to maintain the plasmid in E. coli and a gentamycin resistance gene used to select for mammalian cells transfected with this plasmid vector. Transcription of the gentamycin resistance gene (neo) is directed by the SV40 early region promoter.
  • Known DNA regulatory sequences for the immunoglobulin heavy and light chains are also included in these transfection vectors [Calame, Annual Rev. Immunol.
  • Protoplasts of these bacterial cells prepared by treatment with lyzozyme and EDTA, are fused via polyethylene glycol treatment or electroporation) with the immunoglobulin nonproducing mouse SP2/0 myeloma cell line (ATCC CRL 1581).
  • Transfected SP2/0 cells are isolated using medium containing gentamycin, hypoxanthine, mycophelolic acid and xanthine.
  • the resulting transfectomas are screened for production of mouse:human chimeric SR-1 antibodies using the techniques described in Example 2.
  • Example 4 Assay to Determine Binding of Monoclonal Antibody SR-1 to SCF Receptor .
  • COS-1 cells were transfected with a vector containing the transmembrane and external domain of human c-kit [Zsebo et al., Cell 63 :213-224 (1990)], or with the vector alone.
  • Indirect immunofluorescence analysis using SR-1 followed by FITC-conjugated goat anti-mouse IgG showed that SR-1 recognized none of the cells transfected with vector alone and 5 to 10% of the cells transfected with c-kit. This demonstrates that SR-1 binds to c-kit .
  • SR-1 and indirect immunofluorescence analysis can be used to identify cells that express c-kit.
  • SR-1 antibodies have also been directly conjugated to PE, and this preparation has been used to identify cells that display c-kit.
  • Alternative methods are biotinylation of the SR-1 antibody, with binding of this preparation detected using avidin or streptavidin conjugated to FITC or PE.
  • Example 5 Assay to Determine Inhibition of SCF Binding to SCF Receptor by Monoclonal Antibody SR-1.
  • Cells that express the SCF receptor were incubated with 125 IhSCF (100 picomolar) with or without varying quantities of SR-1 antibody. Preferably, a dilution of 1:1000 to 1:100,000 of SR-1 ascites is used. At the conclusion of the incubation, cell associated 125 IhSCF was separated from free 125 IhSCF by sedimenting the cells through phthalate oil [Broudy et al., Blood 75 :1622-1626 (1990)]
  • the ascites blocks binding of 125 IhSCF to OCIM1 cells at a 1:100,000 dilution (Table 2).
  • This monoclonal antibody is specific for the human SCF receptor in that it does not block binding of 125 I-ratSCF to the murine MC/9 cell line.
  • COS-1 cells were also transfected with V19.8, Zsebo et al., Cell 63:213-224 (1990 or V19.8 containing human c-kit.
  • the COS cell membranes were incubated with 1 nanomolar 125 IhSCF with or without cold SCF or SR-1 ascities (diluted 1:1000) and bound labelled SCF measured.
  • SR-1 blocked binding of 125 IhSCF to c-kit as effectively as unlabelled SCF ( Figure 7).
  • SR-1 blocks the biologic effects of SCF on colony growth.
  • SCF stimulates the growth of early erythroid colony forming cells (BFU-E), and SR-1 blocks this effect.
  • BFU-E early erythroid colony forming cells
  • SR-1 blocks this effect.
  • SCF does not alter the growth of more mature erythroid colony forming cells (CFU-E) and SR-1 has no effect on CFU-E growth.
  • Example 7 Conjugation of Monoclonal Antibody SR-1 to a Therapeutic Agent .
  • SR-1 is coupled or conjugated to a variety of agents, for therapeutic and diagnostic use of the resulting conjugates, Scheinberg et al., Oncology 1, 31-37 (1987).
  • antibody or antibody fragments are coupled to radioisotopes such as 123 I, 131 I, 111 In, 90 Y, 99 Tc.
  • radioisotopes such as 32 P, 131 I, 90 Y, 186 Re, 212 Pb, 212 Bi [Scheinberg et al., Oncology 1, 31-37 (1987) and Humm, J. L., J. Nuclear Medicine 27, 1490-1497 (1986)].
  • Conjugation of radioisotopes to antibody is accomplished by direct attachment of radioisotopes to antibody by methods that include pertinning techniques [Schwartz J., Nuclear Medicine 28, 721 (1987) and Rhodes et al., J. Nuclear Medicine 21, 54 (1980)]; or by way of bifunctional chelate linkers such as those utilizing diethylenetriaminepentaacetic acid (DTPA) [Hnatowich et al., J. Nuclear Medicine 26:503-509 (1985)], N 2 S 2 [Fritzberg et al. Proc. Natl. Acad. Sciences U.S.A. 85:4025 (1988)], or macrocyclic chelators [Moi et al., Cancer Research (Suppl.) 50:7895-7935 (1990)], which bind both antibody and radioisotope.
  • DTPA diethylenetriaminepentaacetic acid
  • a variety of other toxic agents are attached to antibody.
  • these include antitumor drugs and antibiotics which are toxic by way of interaction with DNA via intercalation (e.g., daunomycin, adriamycin, aclacinomycin) or cleavage of DNA (e.g., esperamycin, calicheamycin, neocarzinostatin), and other toxic cytostatic drugs such as cis-platinum, vinblastine, and methotrexate [Scheinberg et al., Oncology 1:31-37 (1987); Greenfield et al., Antibody, Immunoconjugates, and Radiopharmaceuticals 4:107-119 (1991); Dillman et al., Cancer Research 48:6097-6101 (1988);Hamann et al., Abstracts of 197th American Chemical Society National Meeting, Dallas, Texas, U.S.A., April 9-14, 1989, Abstract No.
  • bacterial toxins such as Diphtheria toxin, Shigella toxin, and Pseudomonas exotoxin
  • plant toxins such as ricin, abrin, modeccin, viscumin, pokeweed antiviral protein, saporin, momordin, and gelonin.
  • the toxins contain a catalytic fragment and in some cases fragments or domains that recognize cell surface structures or facilitate translocation across cell membranes.
  • modified toxins or toxin fragments which permit improved specificity without loss of potency (e.g., modified toxins which themselves lack the capability for cell surface recognition, so that such recognition is provided only by the antibody to which conjugation is done, but which retain the membrane translocation capability which enhances potency) [Hnatowich et al., J. Nuclear Medicine 26:503-509 (1985)].
  • toxins fused to a c-kit binding component of antibody are generated by recombinant expression of genetically-engineered elements of toxin and antibody genes joined as a continuous genetic element.
  • conjugated antibodies Prior to diagnostic or therapeutic use, conjugated antibodies are tested to judge their toxic potency, target specificity, in vitro and in vivo stability, and other properties, [Blättler et al., Cancer Cells 1:50-55 (1989) and Immunotoxins, Edited by A. E. Frankel Kluwer Academic Publishers, Boston (1988)]. It is desired that the toxicity of the toxic agent, and the binding affinity and specificity of the antibody, be minimally affected by the coupling procedures used. Thus conjugates are tested for binding to SCF receptor (see Example 3), and inhibition of SCF binding to SCF receptor (see Example 4).
  • In vitro toxicity toward target cells such as the erythroleukemia cell line OCIM1 is tested by measuring incorporation of labeled compounds into macromolecules in treated versus untreated cell cultures, and more directly by determining the number of cells in treated versus untreated cultures that are able to grow in clonogenic and cell growth back-extrapolation assays.
  • In vivo stability, clearance, and specific toxicity are judged by administration of conjugate to appropriate animal recipients.
  • Such recipients include normal mice and in vivo tumor and leukemia xenograft models comprising human neoplastic cells introduced into immunodeficient strains of mice, such as the nude mouse or SCID mouse.
  • Example 8 Preparation of Pharmaceutical Composition Containing Monoclonal Antibody SR-1.
  • compositions of the present invention include an effective amount of the active ingredient, SR-1, alone or in combination with a suitable buffer, diluent and/or additive.
  • Such compositions are provided as sterile aqueous solutions or as lyophilized or otherwise dried formulations.
  • antibodies are formulated in such vehicles at concentrations from about 1 mg/ml to 10 mg/ml.
  • a suitable pharmaceutical composition for injection contains monoclonal antibody SR-1 (1 mg/ml) in a buffered solution (pH 7.0 ⁇ 0.5) of monobasic sodium phosphate (0.45 mg/ml) and Tween® 80 (0.2mg/ml) in sterile H 2 O.
  • Example 9 Selection of Cells Containing SCF Receptors .
  • Cells expressing SCF receptors were selected by direct immune adherence, and the proliferative potential of these cells was determined in colony assays.
  • Monocyte-depleted normal human marrow mononuclear cells were separated by direct immune adherence with SR-1, and cultured in erythropoietin plus IL-3 in semisolid medium for 14 days. The data represent the average of duplicate plates from 1 of 3 experiments.
  • the cells were cultured in suspension for 12 days. At 3 day intervals, aliquots of cells were removed and replated in methylcellulose colony assays to quantitate progenitors. The results show that the SR-1 adherent cells generated large numbers of BFU-E and CFU-GM (up to 3-fold above input) throughout the 12 day suspension culture period. The number of BFU-E and CFU-GM in the SR-1 non-adherent population did not increase above input, and continuously declined. This indicates that the SR-1 adherent population of cells contains more primitive hematopoietic cells that are capable of generating progenitor cells.
  • Example 10 Fluorescence Activated Cell Sorting of Cells Displaying SCF Receptors.
  • SR-1 fluorescence activated cell sorting
  • the SR-1 monoclonal antibody was either (1) conjugated with the fluorescence label FITC or PE; (2) conjugated with biotin and mixed with avidin or streptoavidin which is conjugated with FITC or PE; or (3) further mixed with a goat anti-mouse FITC or a sheep anti-mouse FITC.
  • Such directly labelled or indirectly labelled SCF-receptor-containing cells were then separated on the basis of the level of fluorescence using standard FACS methods.

Claims (25)

  1. Ein monoklonaler Antikörper, der an ein Epitop auf einem SCF-Rezeptor bindet, erhältlich durch Expression von der Hybridom-Zellinie ATCC Nr. HB 10716.
  2. Monoklonaler Antikörper nach Anspruch 1, wobei der SCF-Rezeptor ein menschlicher SCF-Rezeptor ist.
  3. Monoklonaler Antikörper nach Anspruch 1, wobei der monoklonale Antikörper ein Maus-Mensch-Hybrid-Antikörper ist.
  4. Monoklonaler Antikörper nach Anspruch 2, wobei der monoklonale Antikörper von der Hybridom-Zellinie ATCC Nr. HB 10716 produziert wird.
  5. Monoklonaler Antikörper nach Anspruch 1, wobei der Antikörper vom IgG2a Isotyp ist.
  6. Monoklonaler Antikörper nach Anspruch 1, weiter umfassend eine Fähigkeit zur Hemmung der Bindung eines SCF-Moleküls an den SCF-Rezeptor.
  7. Monoklonaler Antikörper nach Anspruch 6, wobei das SCF-Molekül ein menschliches SCF-Molekül ist.
  8. Monoklonaler Antikörper nach Anspruch 6, wobei der SCF-Rezeptor ein menschlicher SCF-Rezeptor ist.
  9. Ein Verfahren zur Aufreinigung hämatopoetischer Zellen, umfassend die Schritte:
    (a) Exponieren eines Zellgemisches an einen monoklonalen Antikörper nach Anspruch 1,
    (b) Abtrennen der Zellen, die an den monoklonalen Antikörper binden, von Zellen, die nicht an den monoklonalen Antikörper binden.
  10. Verfahren zur Aufreinigung hämatopoetischer Zellen nach Anspruch 9, wobei die Abtrennung durch Säulenchromatographie erfolgt.
  11. Verfahren zur Aufreinigung hämatopoetischer Zellen nach Anspruch 9, wobei die Abtrennung durch fluoreszenzaktivierte Zellsortierung erfolgt.
  12. Verfahren zur Aufreinigung hämatopoetischer Zellen nach Anspruch 9, wobei die Abtrennung durch direkte Immunadhärenz erfolgt.
  13. Ein in-vitro-Verfahren zur Rekonstitution hämatopoetischer Zellen, umfassend eine Knochenmarktransplantation mit hämatopoetischen Zellen, die mit dem Verfahren nach Anspruch 9 aufgereinigt wurden.
  14. Ein in-vitro-Verfahren zur Gentherapie, umfassend einen retroviral-vermittelten Gentransfer in Zellen, die nach Anspruch 9 aufgereinigt wurden.
  15. Ein in-vitro-Verfahren zur Abtrennung normaler Zellen von neoplastischen Leukämiezellen, umfassend die Schritte:
    (a) Exponieren eines Zellgemisches, umfassend normale Zellen und neoplastische Leukämiezellen, an einen monoklonalen Antikörper nach Anspruch 1,
    (b) Abtrennen normaler Zellen von neoplastischen Leukämiezellen, basierend auf einem Unterschied in der Anzahl von SCF-Rezeptoren auf normalen Zellen und neoplastischen Leukämiezellen.
  16. Ein in-vitro-Verfahren zur Behandlung von Leukämiezellen, umfassend die Verabreichung einer therapeutisch wirksamen Menge eines therapeutischen Leukämie-Mittels, das an einen monoklonalen Antikörper nach Anspruch 1 gekoppelt ist.
  17. Ein in-vitro-Verfahren zur Behandlung von Leukämiezellen, umfassend die Verabreichung einer therapeutisch wirksamen Menge eines therapeutischen Leukämie-Mittels, das an ein Bindungsfragment eines monoklonalen Antikörpers nach Anspruch 1 gekoppelt ist.
  18. Die Verwendung eines monoklonalen Antikörpers nach Anspruch 1, gekoppelt an ein therapeutisches anti-neoplastisches Mittel, zur Herstellung eines Arzneimittels zur Behandlung neoplastischer Zellen.
  19. Ein Arzneimittel, umfassend ein therapeutisches anti-neoplastisches Mittel, gekoppelt an einen monoklonalen Antikörper nach Anspruch 1, zur Behandlung neoplastischer Zellen.
  20. Ein Verfahren zur Bestimmung des Vorkommens von SCF-Rezeptoren in einer Zellprobe, umfassend die Schritte:
    (a) Exponieren einer Zellprobe mit einem monoklonalen Antikörper nach Anspruch 1,
    (b) Feststellen der Bindung des monoklonalen Antikörpers an SCF-Rezeptoren.
  21. Verfahren nach Anspruch 20, wobei die Feststellung unter Verwendung eines markierten monoklonalen Antikörpers durchgeführt wird.
  22. Verfahren nach Anspruch 20, wobei die Zellprobe ausgewählt ist aus der Gruppe enthaltend normale Zellen, Leukämiezellen und solide Tumorzellen.
  23. Ein Arzneimittel zur Modifizierung der Sensitivität von Zellzyklus-spezifischen chemotherapeutischen Mitteln, umfassend eine SCF-hemmende Menge eines monoklonalen Antikörpers nach Anspruch 1.
  24. Eine Hybridomzelle, die zur Herstellung eines monoklonalen Antikörpers nach Anspruch 1 fähig ist.
  25. Eine Hybridomzelle nach Anspruch 24, die bei der ATCC unter der Hinterlegungsnummer HB 10716 hinterlegt ist.
EP92910836A 1991-04-05 1992-04-03 Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor Expired - Lifetime EP0578774B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68124591A 1991-04-05 1991-04-05
US681245 1991-04-05
PCT/US1992/002674 WO1992017505A1 (en) 1991-04-05 1992-04-03 Monoclonal antibodies to stem cell factor receptors

Publications (3)

Publication Number Publication Date
EP0578774A1 EP0578774A1 (de) 1994-01-19
EP0578774A4 EP0578774A4 (en) 1995-11-15
EP0578774B1 true EP0578774B1 (de) 1998-07-29

Family

ID=24734435

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92910836A Expired - Lifetime EP0578774B1 (de) 1991-04-05 1992-04-03 Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor

Country Status (10)

Country Link
US (5) US5489516A (de)
EP (1) EP0578774B1 (de)
JP (1) JP3213314B2 (de)
AT (1) ATE169031T1 (de)
CA (1) CA2107553C (de)
DE (1) DE69226431T2 (de)
DK (1) DK0578774T3 (de)
ES (1) ES2118820T3 (de)
HK (1) HK1008827A1 (de)
WO (1) WO1992017505A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT62011A (en) * 1989-10-16 1993-03-29 Amgen Inc Process for producing factors influencing the functioning of stem cells
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
ES2118820T3 (es) * 1991-04-05 1998-10-01 Univ Washington Anticuerpos monoclonales para receptores de factores de celulas pluripotentes.
EP0548867A2 (de) * 1991-12-23 1993-06-30 Yeda Research And Development Co. Ltd. Wasserlöslicher Stammzellenfaktor-Rezeptor
FR2700471B1 (fr) * 1993-01-21 1995-04-07 Pasteur Merieux Serums Vacc Utilisation d'anticorps monoclonaux anti-LFA-1 pour la préparation d'un médicament destiné à prévenir le rejet des greffes d'organes solides et médicaments obtenus.
US5911988A (en) * 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
US5824789A (en) * 1995-06-07 1998-10-20 Systemix, Inc. Human growth factors, nucleotide sequence encoding growth factors, and method of use thereof
DE19600589C1 (de) 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
CA2264610A1 (en) * 1996-11-05 1998-05-14 Bristol-Myers Squibb Company Branched peptide linkers
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6737249B1 (en) * 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
SE9803712L (sv) * 1998-10-29 1999-12-20 Henrik Willers Förfarande och anordning för förankring av en boj
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
EP1263463B1 (de) * 2000-03-06 2011-05-25 University of Kentucky Research Foundation Verwendung eines antikörpers oder eines immunotoxins, der bzw. das selektiv an cd123 bindet zur beeinträchtigung hämatologischer krebs-vorläuferzellen
US20050064587A1 (en) * 2001-09-07 2005-03-24 Lawrence Rosenberg Pancreatic small cells and uses thereof
US7754155B2 (en) * 2002-03-15 2010-07-13 Ross Amelia A Devices and methods for isolating target cells
US20030175818A1 (en) * 2002-03-15 2003-09-18 Ross Amelia A. Devices and methods for isolating and recovering target cells
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003241313A1 (en) * 2002-04-23 2003-11-10 Roger Williams Hospital Compositions and methods for stem cell delivery
US7577297B2 (en) * 2002-12-16 2009-08-18 Canon Kabushiki Kaisha Pattern identification method, device thereof, and program thereof
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
WO2008030538A2 (en) * 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
EP3960764A1 (de) 2006-11-03 2022-03-02 The Board of Trustees of the Leland Stanford Junior University Selektive immundepletion einer endogenen stammzellennische zur transplantation
WO2008127735A1 (en) 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
WO2012050925A2 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Highly soluble leptins
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
EP2668210B1 (de) 2011-01-26 2020-06-17 Celldex Therapeutics, Inc. Anti-kit-antikörper und ihre verwendungen
BR112015001459B1 (pt) 2012-07-25 2023-02-14 Celldex Therapeutics, Inc Anticorpo isolado ou fragmento do mesmo, conjugado, usos dos mesmos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, célula isolada, kit, método in vitro para inibir atividade da kit, método para produzir um anticorpo
MA38396B1 (fr) 2013-03-15 2019-05-31 Novartis Ag Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
WO2015050959A1 (en) * 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
EP3145543A4 (de) 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Behandlung von eosinophil- oder mastzellenvermittelten erkrankungen
JP6830059B2 (ja) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド スケジュール化された細胞フィーディング
US10889646B2 (en) 2015-03-25 2021-01-12 Children's Hospital Medical Center Use of KIT inhibitors to condition subjects for a hematopoietic stem cell (HSC) transplantation
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
SG11201811290VA (en) 2016-06-17 2019-01-30 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+cells
IL268058B2 (en) 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for depleting cd137 plus cells
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2019066093A1 (ko) * 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
WO2023111311A1 (en) 2021-12-16 2023-06-22 Universität Basel Discernible cell surface protein variants of cd117 for use in cell therapy
WO2024008910A1 (en) 2022-07-07 2024-01-11 Cimeio Therapeutics Ag Antibodies targeting cd117

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5081030A (en) * 1989-04-25 1992-01-14 The Johns Hopkins University Release of cells from affinity matrices
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
ES2118820T3 (es) * 1991-04-05 1998-10-01 Univ Washington Anticuerpos monoclonales para receptores de factores de celulas pluripotentes.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD(1992), Vol.79, no.2, P.338-346, Broudy et al. *

Also Published As

Publication number Publication date
DE69226431D1 (de) 1998-09-03
JP3213314B2 (ja) 2001-10-02
DK0578774T3 (da) 1999-04-26
EP0578774A4 (en) 1995-11-15
US20020018775A1 (en) 2002-02-14
US5489516A (en) 1996-02-06
HK1008827A1 (en) 1999-05-21
EP0578774A1 (de) 1994-01-19
CA2107553A1 (en) 1992-10-06
US5906938A (en) 1999-05-25
DE69226431T2 (de) 1999-04-22
US5919911A (en) 1999-07-06
ATE169031T1 (de) 1998-08-15
WO1992017505A1 (en) 1992-10-15
ES2118820T3 (es) 1998-10-01
CA2107553C (en) 2001-07-31
JPH06506833A (ja) 1994-08-04
US5922847A (en) 1999-07-13

Similar Documents

Publication Publication Date Title
EP0578774B1 (de) Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
CA1341082C (en) Method of treating tumor cells by inhibiting growth factor receptor function
US6107469A (en) Minimum recognition unit of a pem mucin tandem repeat specific monoclonal antibody
EP0637593B1 (de) Bispezifische Auslösemoleküle, die das Lymphozytantigen CD2 und Tumorantigene erkennen
US8409573B2 (en) Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
JPH0159870B2 (de)
JP2001521520A (ja) 抗α▲下ｖ▼β▲下３▼インテグリン抗体アンタゴニスト
EP0737251A1 (de) Antikörper gegen EGF - Rezeptor und ihre Antitumorwirkung
JPH0159869B2 (de)
US7592005B2 (en) Monoclonal antibody
KR20070002029A (ko) 항 인간 테나신 단클론 항체
US5407805A (en) Monoclonal antibody reactive to various human leukemia and lymphoma cells and methods of using same for diagnosis and treatment
WO1993002105A1 (en) Trifunctional compounds having specificity for multi-drug resistant cells
Faulk et al. Transferrin receptor growth control in normal and transformed cells
EP0668923B1 (de) Monoklonaler antikörper
Fleenor Characterization of three monoclonal antibodies directed against a bovine cerebral cortex cell surface sialoglycopeptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931004

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19961114

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

REF Corresponds to:

Ref document number: 169031

Country of ref document: AT

Date of ref document: 19980815

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69226431

Country of ref document: DE

Date of ref document: 19980903

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2118820

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

ET Fr: translation filed
REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20090316

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20090508

Year of fee payment: 18

Ref country code: DK

Payment date: 20090415

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20090407

Year of fee payment: 18

Ref country code: NL

Payment date: 20090405

Year of fee payment: 18

Ref country code: LU

Payment date: 20090424

Year of fee payment: 18

Ref country code: IT

Payment date: 20090423

Year of fee payment: 18

Ref country code: FR

Payment date: 20090417

Year of fee payment: 18

Ref country code: DE

Payment date: 20090327

Year of fee payment: 18

Ref country code: AT

Payment date: 20090415

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20090330

Year of fee payment: 18

Ref country code: BE

Payment date: 20090428

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20090416

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090401

Year of fee payment: 18

BERE Be: lapsed

Owner name: THE *BOARD OF REGENTS OF THE UNIVERSITY OF WASHING

Effective date: 20100430

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20101101

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100403

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20101230

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101101

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101103

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100403

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100403

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101103

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100503

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20110708

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100403

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100404